Riociguat for pulmonary arterial hypertension associated with congenital heart disease

Browse by...

Deposit

Highlights

More informations

Title		Riociguat for pulmonary arterial hypertension associated with congenital heart disease
Authors		Rosenkranz, Stephan Ghofrani, Hossein-Ardeschir Beghetti, Maurice Ivy, Dunbar Frey, Reiner Fritsch, Arno Weimann, Gerrit Saleh, Soundos Apitz, Christian show all authors [1 - 9]
Published in		Heart. 2015, vol. 101, no. 22, p. 1792-1799
Abstract		The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH after correction of congenital heart disease (PAH-CHD) from the PATENT studies.
Identifiers		DOI: 10.1136/heartjnl-2015-307832 PMID: 26135803
Full text		Article (Published version) (1.2 MB) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique
Research group		L'hypertension pulmonaire (pédiatrie) (228)
Citation (ISO format)		ROSENKRANZ, Stephan et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. In: Heart, 2015, vol. 101, n° 22, p. 1792-1799. doi: 10.1136/heartjnl-2015-307832 https://archive-ouverte.unige.ch/unige:76378